Table 2.
Effect of missing KIR ligands on transplantation outcome
| Group | Cohort size | Relapse* | aGVHD (grades II-IV)* | TRM* | DFS† | ||||
|---|---|---|---|---|---|---|---|---|---|
| Hazard ratio (95% CI) | P | Hazard ratio (95% CI) | P | Hazard ratio (95% CI) | P | Hazard ratio (95% CI) | P | ||
| AML and MDS | 105 | ||||||||
| All KIR-L present | 38 | 1.00 (reference) | — | 1.00 (reference) | — | 1.00 (reference) | — | 1.00 (reference) | — |
| Missing 1 or more KIR-L | 67 | 0.79 (0.40-1.59) | .52 | 1.56 (0.79-3.08) | .20 | 2.19 (0.61-7.80) | .23 | 0.91 (0.50-1.65) | .74 |
| Missing HLA-C1 | 14 | 0.66 (0.20-2.16) | .49 | 1.68 (0.57-4.91) | .34 | 0.26 (0.03-2.43)‡ | .24‡ | 1.81 (0.66-4.95) | .25 |
| Missing HLA-C2 | 17 | 0.73 (0.27-1.96) | .53 | 2.87 (1.29-6.37) | .01 | 4.01 (0.98-16.40) | .05 | 0.68 (0.29-1.57) | .36 |
| Missing HLA-Bw4 | 9 | 0.68 (0.14-3.32) | .63 | 0.61 (0.12-3.05) | .55 | 0.29 (0.02-3.74)‡ | .36‡ | 1.71 (0.53-5.49) | .37 |
| Missing HLA-Bw4 and HLA-C1 or HLA-C2 | 27 | 0.90 (0.41-1.95) | .78 | 1.26 (0.51-3.12) | .62 | 0.43 (0.15-1.24) | .12 | 0.66 (0.32-1.36) | .25 |
| AML | 81 | ||||||||
| All KIR-L present | 28 | 1.00 | 1.00 | 1.00 | 1.00 | ||||
| Missing 1 or more KIR-L | 53 | 0.91 (0.40-2.08) | .84 | 1.52 (0.65-3.57) | .33 | 1.05 (0.26-4.17) | .94 | 0.91 (0.45-1.86) | .80 |
| MDS | 24 | ||||||||
| All KIR-L present | 10 | 1.00 | 1.00 | 1.00 | 1.00 | ||||
| Missing 1 or more KIR-L | 14 | 0.38 (0.10-1.45) | .15 | 1.80 (0.59-5.51) | .30 | 3.57 (0.71-17.9)‡ | .08‡ | 0.80 (0.27-2.40) | .69 |
| Subgroups of AML and MDS | |||||||||
| Patient with ATG treatment | 23 | ||||||||
| All KIR-L present | 12 | 1.00 | 1.00 | 1.00 | 1.00 | ||||
| Missing 1 or more KIR-L | 11 | 1.11 (0.34-3.58) | .86 | 0.36 (0.04-3.35) | .37 | 1.14 (0.08-16.05) | .92 | 1.00 (0.25-4.03) | 1.00 |
| Patient without ATG treatment | 82 | ||||||||
| All KIR-L present | 26 | 1.00 | 1.00 | 1.00 | 1.00 | ||||
| Missing 1 or more KIR-L | 56 | 0.78 (0.33-1.84) | .57 | 1.63 (0.76-3.51) | .22 | 2.41 (0.52-11.12) | .26 | 0.86 (0.42-1.77) | .69 |
| Patient receiving BM grafts | 35 | ||||||||
| All KIR-L present | 10 | 1.00 | 1.00 | 1.00 | 1.00 | ||||
| Missing 1 or more KIR-L | 25 | 0.51 (0.21-1.25) | .14 | 1.15 (0.32-4.11) | .83 | 2.01 (0.23-17.39) | .52 | 1.45 (0.57-3.68) | .43 |
| Patient receiving PBSC grafts | 70 | ||||||||
| All KIR-L present | 28 | 1.00 | 1.00 | 1.00 | 1.00 | ||||
| Missing 1 or more KIR-L | 42 | 1.17 (0.43-3.19) | .76 | 1.67 (0.75-3.72) | .21 | 2.23 (0.46-10.68) | .32 | 0.71 (0.31-1.59) | .40 |
| Patient with MAC | 76 | ||||||||
| All KIR-L present | 22 | 1.00 | 1.00 | 1.00 | 1.00 | ||||
| Missing 1 or more KIR-L | 54 | 0.68 (0.29-1.59) | .38 | 1.32 (0.62-2.84) | .48 | 2.14 (0.46-9.86) | .33 | 0.98 (0.47-2.06) | .97 |
| Patient with RIC | 29 | ||||||||
| All KIR-L present | 16 | 1.00 | 1.00 | 1.00 | 1.00 | ||||
| Missing 1 or more KIR-L | 13 | 1.31 (0.40-4.25) | .66 | 0.81 (0.15-4.46) | .81 | 1.31 (0.09-18.83) | .84 | 0.74 (0.23-2.34) | .61 |
KIR-L indicates KIR ligand; PBSC, peripheral blood stem cell; and MAC, myeloablative conditioning.
*
Values obtained by proportional subdistribution hazard regression model of Fine and Gray in a competing risks setting. Competing events were relapse (for TRM), death without aGVHD within 100 days after the transplantation (for aGVHD), and death without relapse (for relapse).
†
Hazard ratio and confidence interval (CI) obtained by the Mantel-Haenszel method, P values by log-rank test.
‡
Values obtained by the Mantel-Haenszel method, P values by log-rank test via GraphPad Prism software. (Fine and Gray analysis could not be used due to zero events in one of the groups.)